Form D · Biotechnology
Schrodinger, Inc.
New York, NY · CIK 0001490978
Offering snapshot reported May 8, 2019 · SEC filing
- Reported sold
- $108M Offering amount: $115M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 9, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2019 | Amendment | $107,824,987 | No comparison | 13 | SEC filing |
| Jun 19, 2015 | Initial | $22,000,000 | No comparison | 2 | SEC filing |
| Dec 17, 2012 | Initial | $20,000,000 | No comparison | 1 | SEC filing |
| May 5, 2010 | Initial | $10,000,000 | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-325797
Source: Form D, filed May 8, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles Ardai | Director |
| Cony D'cruz | Executive |
| Joshua Distler | Director |
| Ramy Farid | Director, Executive |
| Richard Friesner | Director |
| Wayne Guida | Director |
| Rosana Kapeller Liebermann | Director |
| Joel Lebowitz | Executive |
| Michael Lynton | Director |
| Murco Ringnalda | Executive |
| Louis Salkind | Director |
| Yvonne Tran | Executive |
| Timothy Wright | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
120 West 45 Th Street 17 Th Floor
New York, NY, 10036
New York, NY, 10036